{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2004"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2020223"],"location":["Japan"],"study_start_month":["1"],"keyword":["Irinotecan","Irinotecan, S-1, Phase II, colorectal cancer,"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer","description":"To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative colorectal cancer.","dates":{"creation":"2004-01-15"},"accession":"2020223","cross_references":{"ClinicalTrials___gov":["NCT00209651"]}}